Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients Anna Bandurska-Luque,

Slides:

Advertisements

Similar presentations

Albert J. Chang, MD, PhD 1 Farrokh Dehdashti, MD 2 Perry W. Grigsby, MD, MS 1 Department of Radiation Oncology 1 Department of Radiology and Nuclear Medicine.

Advertisements

HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma:

Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters Catharina M.L. Zegers, Wouter van Elmpt, Roel Wierts, Bart Reymen,

Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one.

A Royal College of Radiologists National Audit of Radiotherapy in the Treatment of Metastatic Spinal Cord Compression and Implications for the Development.

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

Ultrasound stratification of the FDG-avid thyroid nodule

Automatic treatment planning improves the clinical quality of head and neck cancer treatment plans Christian Rønn Hansen, Anders Bertelsen, Irene Hazell,

Simultaneous positron emission tomography (PET) assessment of metabolism with 18F- fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine.

Treatment of Primary Varicose Veins by Endovenous Obliteration with the VNUS Closure System: Results of a Prospective Multicentre Study Ph. Nicolini,

Fig. 10. MIP (A, C) and axial non contrast fused 18F-FDG PET/CT (B) in 20-year-old man with ALK positive anaplastic large cell lymphoma. A. Patient had.

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy Chiara De-Colle, David Mönnich, Stefan Welz, Simon Boeke,

Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced.

FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies Marcelo F.K. Benveniste, MD, Cesar A.

Can Imaging Parameters Provide Information Regarding Histopathology in Head and Neck Squamous Cell Carcinoma? A Meta-Analysis Alexey Surov, Hans Jonas.

Volume 59, Issue 2, Pages (February 2011)

Treatment of Alcohol Withdrawal in Hospitalized Patients

Improved outcome of treating locally advanced lung cancer with the use of Lattice Radiotherapy (LRT): A case report Beatriz E. Amendola, Naipy C. Perez,

Michele A. Hanson, M.D., Daniel A. Dumesic, M.D.

Clinical and Translational Radiation Oncology

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Clinical and Translational Radiation Oncology

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy Chiara De-Colle, David Mönnich, Stefan Welz, Simon Boeke,

Automatic treatment planning improves the clinical quality of head and neck cancer treatment plans Christian Rønn Hansen, Anders Bertelsen, Irene Hazell,

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Retrospective assessment of MRI-based volumetric changes of normal tissues in glioma patients following radio(chemo)therapy Andreas Gommlich, Felix Raschke,

Surgery vs. primary radiotherapy in early-stage oropharyngeal cancer

Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma Amanda J. Walker, MD, Alin Chirindel, MD, Robert.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Volume 383, Issue 9935, Pages (June 2014)

Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report Lore Helene Braun, Stefan.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after.

The impact of 18F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: Results from Westmead Hospital, Sydney, Australia Rebecca.

Redefining Appropriate Treatment Expectations

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed.

Jojanneke M. Seinen, Maarten G

Axillary radiotherapy for nodal lymphoma: What CTV expansion is required to account for absence of pre-chemotherapy treatment position FDG PET-CT? Robin.

Clinical and Translational Radiation Oncology

Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma Annett Linge, Ricarda Rauschenberg, Sophia Blum,

Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer Steen Riisgaard.

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and.

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

Gross tumour delineation on computed tomography and positron emission tomography- computed tomography in oesophageal cancer: A nationwide study M.E. Nowee,

Follow up results of a prospective study to evaluate the impact of FDG-PET on CT- based radiotherapy treatment planning for oesophageal cancer Sweet Ping.

Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.

Jean-Emmanuel Bibault, Ingeborg Tinhofer

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT Rosario Mazzola, MD, Alba Fiorentino,

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor.

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Volume 17, Issue 2, Pages (February 1950)

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy Rebecca Bütof, Calogero Gumina, Chiara Valentini, Antje.

Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses Raul E. Melo, MD, Dirceu Solé,

It’s All in the “Swerve of the Curve”

Olga Vornicova, MD, Gil Bar-Sela, MD JAAD Case Reports

Mohsen Beheshti, MD, FASNC, FEBNM PET Clinics

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Patterns of practice in palliative radiotherapy for bleeding tumours in the Netherlands; a survey study among radiation oncologists Jennifer Strijbos,

EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes—an International Multi-Centre Experience Robert C. Rintoul, FRCP, PhD, Kurt.

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Constantinos Zamboglou, Matthias Eiber, Thomas R

Volume 4, Issue 1, Pages (February 2006)

Volume 4, Issue 1, Pages 2-3 (February 2006)

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Clinicopathologic Factors Associated With Occult Lymph Node Metastasis in Patients With Clinically Diagnosed N0 Lung Adenocarcinoma Youngkyu Moon, MD,

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients Anna Bandurska-Luque, Steffen Löck, Robert Haase, Christian Richter, Klaus Zöphel, Rosalind Perrin, Steffen Appold, Mechthild Krause, Jörg Steinbach, Jörg Kotzerke, Frank Hofheinz, Daniel Zips, Michael Baumann, Esther G.C. Troost Clinical and Translational Radiation Oncology Volume 15, Pages 108-112 (February 2019) DOI: 10.1016/j.ctro.2019.02.002 Copyright © 2019 Terms and Conditions

Fig. 1 Scatterplots showing the correlation between FMISO uptake in the primary tumour and in lymph node metastases in 15 patients with large lymph node metastases (>5 ml on FDG-PET/CT) at four time-points before and during treatment. The Spearman correlation coefficient ρ significantly differed from 0 prior to and in week 2 and 5 of treatment (TBRpeak – tumour to background peak). Clinical and Translational Radiation Oncology 2019 15, 108-112DOI: (10.1016/j.ctro.2019.02.002) Copyright © 2019 Terms and Conditions

Fig. 2 Scatterplot showing the correlation between FMISO uptake in the primary tumour and in lymph node metastases in all assessed patients before initiation of treatment. The SUVmax values were corrected for partial volume effect according to [26]. The Spearman correlation coefficient ρ significantly differed from zero (p = 0.015). (SUVmax – maximum standardized uptake value, PVE – partial volume effect). Clinical and Translational Radiation Oncology 2019 15, 108-112DOI: (10.1016/j.ctro.2019.02.002) Copyright © 2019 Terms and Conditions